1-(5-tert-butyl-2-phenyl-2h-pyrazol-3-yl)-3-[2-fluoro-4-(1-methyl-2-oxo-2,3-dihydro-1h-imidazo[4,5-b]pyridin-7-yloxy)-phenyl]-urea and related compounds and their use in therapy
INSTITUTE OF CANCER RESEARCH: ROYAL CANCER HOSPITAL (THE);CANCER RESEARCH TECHNOLOGY LIMITED
发明人:
ZAMBON ALFONSO,NICULESCU-DUVAZ DAN,MENARD DELPHINE,MARAIS RICHARD,SPRINGER CAROLINE,NICULESCU-DUVAZ ION
申请号：
NZ60108511
公开号：
NZ601085A
申请日:
2011.01.27
申请国别(地区):
NZ
年份:
2015
代理人:
摘要：
Disclosed herein is 1-(3-tert-butyl-1-phenyl-1H-pyrazol-5-yl)-3-(2-fluoro-4-(1-N-methyl-2-oxo-2,3-dihydro-1H-imidazo[4,5-b]pyridin-7-yloxy)phenyl)urea and related RA substituted compounds, and the use thereof in the treatment of cancer, such as mutant RAS cancer, more specifically pancreatic cancer； thyroid (e.g., follicular； undifferentiated papillary) cancer； colorectal cancer； seminoma； myelodysplastic syndrome (MDS)； lung cancer (e.g., lung adenocarcinoma)； liver cancer； leukemia (e.g., acute myelogenous leukemia (AML))； melanoma； bladder cancer； kidney cancer； breast cancer, ovarian cancer, bile duct cancer, or glioma.
